Abstract
Thapsigargin was originally isolated from the roots of the Mediterranean umbelliferous plant Thapsia garganica in order to characterize the skin irritant principle. Characteristic chemical properties and semi-syntheses are reviewed. The biological activity was related to the subnanomolar affinity for the sarco/endoplasmic reticulum calcium ATPase. Prolonged inhibition of the pump afforded collapse of the calcium homeostasis and eventually apoptosis. Structure-activity relationships enabled design of an equipotent analogue containing a linker. Conjugation of the analogue containing the linker with peptides, which only are substrates for either prostate specific antigen (PSA) or prostate specific membrane antigen (PSMA) enabled design of prodrugs targeting a number of cancer diseases including prostate cancer (G115) and hepatocellular carcinoma (G202). Prodrug G202 has under the name of mipsagargin in phase II clinical trials shown promising properties against hepatocellular carcinoma.
Keywords: Thapsigargin, mipsagargin, drug development, clinical trials, structure activity relationships, prostate specific antigen, prostate specific membrane antigen, prodrug, anti-angiogenesis.
Current Pharmaceutical Design
Title:Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development
Volume: 21 Issue: 38
Author(s): Nhu Thi Quynh Doan and Soren Brogger Christensen
Affiliation:
Keywords: Thapsigargin, mipsagargin, drug development, clinical trials, structure activity relationships, prostate specific antigen, prostate specific membrane antigen, prodrug, anti-angiogenesis.
Abstract: Thapsigargin was originally isolated from the roots of the Mediterranean umbelliferous plant Thapsia garganica in order to characterize the skin irritant principle. Characteristic chemical properties and semi-syntheses are reviewed. The biological activity was related to the subnanomolar affinity for the sarco/endoplasmic reticulum calcium ATPase. Prolonged inhibition of the pump afforded collapse of the calcium homeostasis and eventually apoptosis. Structure-activity relationships enabled design of an equipotent analogue containing a linker. Conjugation of the analogue containing the linker with peptides, which only are substrates for either prostate specific antigen (PSA) or prostate specific membrane antigen (PSMA) enabled design of prodrugs targeting a number of cancer diseases including prostate cancer (G115) and hepatocellular carcinoma (G202). Prodrug G202 has under the name of mipsagargin in phase II clinical trials shown promising properties against hepatocellular carcinoma.
Export Options
About this article
Cite this article as:
Quynh Doan Thi Nhu and Christensen Brogger Soren, Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development, Current Pharmaceutical Design 2015; 21 (38) . https://dx.doi.org/10.2174/1381612821666151002112824
DOI https://dx.doi.org/10.2174/1381612821666151002112824 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances of Inorganic Materials in the Detection and Therapeutic Uses against Coronaviruses
Current Medicinal Chemistry Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design Flavopiridol, the First Cyclin-Dependent Kinase Inhibitor: Recent Advances in Combination Chemotherapy
Mini-Reviews in Medicinal Chemistry Genes that Modulate the Sensitivity for Anti-Microtubule Drug-Mediated Chemotherapy
Current Cancer Drug Targets The Adenine Nucleotide Translocator: A New Potential Chemotherapeutic Target
Current Drug Targets Nanoparticle Albumin - Bound (NAB) Technology is a Promising Method for Anti-Cancer Drug Delivery
Recent Patents on Anti-Cancer Drug Discovery New Insights in Testing and Imaging Techniques for Solid Tumor Response Evaluation
Neuroscience and Biomedical Engineering (Discontinued) Curcumin: Powerful Immunomodulator from Turmeric
Current Immunology Reviews (Discontinued) Cytotoxic Effects of the Monomer and Dimer of 3, 4-seco-ent-kaurene from Croton Micans and their Interaction with Antitumoral Drugs on Cellular Line of Human Prostate Cancer
Letters in Drug Design & Discovery Biomarkers for Colorectal Cancer: Identification Through Proteomics
Current Proteomics Advances in Cancer Stem Cell Therapy: Targets and Treatments
Recent Patents on Regenerative Medicine Overview on Anticancer Drug Design and Development
Current Medicinal Chemistry Folate-Linked Lipid-Based Nanoparticle for Targeted Gene Delivery
Current Drug Delivery Design and Pre-Clinical Development of Epitope-based DNA Vaccines Against B-Cell Lymphoma
Current Gene Therapy Insulin Secretagogues, Sulfonylurea Receptors and KATP Channels
Current Pharmaceutical Design Target Identification of Grape Seed Extract in Colorectal Cancer Using Drug Affinity Responsive Target Stability (DARTS) Technique: Role of Endoplasmic Reticulum Stress Response Proteins
Current Cancer Drug Targets Vascular Endothelial Growth Factor (VEGF) Inhibition - A Critical Review
Anti-Cancer Agents in Medicinal Chemistry Leveraging Cell Cycle Analysis in Anticancer Drug Discovery to Identify Novel Plasmodial Drug Targets
Infectious Disorders - Drug Targets Gastric Cancer: Nanoparticles as Tools to Improve Treatment Efficacy
Current Pharmaceutical Design PEDF as an Emerging Therapeutic Candidate for Osteosarcoma
Current Cancer Drug Targets